

Table e-1 – Outcomes at baseline and follow-up in subthalamic and pallidal stimulation for the original cohort

	STN-DBS						GPi-DBS						STN- vs. GPi-DBS p ^b
	n	Baseline		Follow-up		p ^a	n	Baseline		Follow-up		p ^a	
		mean	SD	mean	SD			mean	SD	mean	SD		
PDQ SI	40	33.6	13.5	19.8	12.6	<0.001	19	29.3	12.1	16.7	8.7	0.004	0.712
UPDRS-I	40	2.4	1.8	1.6	1.4	0.075	18	2.9	2.3	1.9	1.5	0.071	0.761
UPDRS-II	40	11.5	6.2	8.8	5.9	<0.001	19	9.8	5.4	5.2	4.1	0.007	0.167
UPDRS-III	40	19.5	8.6	17.7	10.0	0.118	19	14.2	7.7	13.8	7.2	0.826	0.018
UPDRS-IV	40	5.4	3.8	2.7	2.9	<0.001	19	4.5	3.0	1.6	1.8	<0.001	0.827
H&Y	39	2.3	0.4	2.3	0.6	0.881	19	2.5	0.5	2.3	0.4	0.166	0.056
S&E	40	83.8	8.1	89.8	8.0	<0.001	19	83.2	9.5	90.0	8.2	0.008	0.799
LEDD	40	1195.6	459.4	582.2	348.2	<0.001	20	1161.0	533.2	1048.8	506.0	0.357	<0.001
NMSS	40	61.4	36.5	38.4	25.1	<0.001	20	61.5	25.8	37.2	14.2	0.002	0.832
Cardiovascular	40	1.2	1.8	1.0	2.4	0.611	20	2.0	2.9	0.7	1.5	0.058	0.250
Sleep/fatigue	40	13.7	8.9	8.7	7.5	0.002	20	14.5	7.4	8.8	6.2	0.004	0.039
Mood/cognition	40	9.6	12.6	4.2	8.1	0.017	20	12.5	13.8	2.2	3.3	0.001	0.490
Perceptual problems/hallucinations	40	1.2	3.4	0.2	0.7	0.007	20	1.0	2.8	0.3	0.6	0.223	0.560
Attention/memory	40	4.1	5.7	2.7	3.3	0.053	20	4.5	4.0	3.6	3.3	0.324	0.208
Gastro-intestinal	40	5.6	5.7	5.8	6.9	0.757	20	4.6	5.2	4.6	5.7	0.959	0.774
Urinary	40	9.4	9.3	6.6	8.7	0.012	20	6.0	5.3	5.6	6.2	0.677	0.085
Sexual function	40	5.1	8.3	2.6	5.0	0.017	20	6.3	5.0	3.2	4.6	0.015	0.379
Miscellaneous	40	11.6	7.5	6.8	7.0	0.003	20	10.4	8.4	8.5	7.0	0.466	0.208

Abbreviations: GPi-DBS = Pallidal stimulation; H&Y = Hoehn and Yahr Scale, LEDD = levodopa equivalent daily dose; NMSS = Non-motor Symptom Scale; PDQ SI = Parkinson's Disease Questionnaire Summary Index; S&E = Schwab and England Scale; STN-DBS = Subthalamic stimulation; UPDRS-I, -II, -III, and -IV = Unified Parkinson's Disease Rating Scale-cognition, -activities of daily living, -motor impairment, and -motor complications.

^a Wilcoxon signed-rank test, respectively paired t-test, when parametric tests were applicable, with Benjamini-Hochberg correction for multiple comparisons due to multiple outcome parameters and two DBS targets.

^b Mann-Whitney U test, respectively unpaired t-test, when parametric tests were applicable, with raw p-values. After Benjamini-Hochberg correction only LEDD in the unmatched cohort remained significant (p<0.001)